What is HC Wainwright’s Estimate for VERA FY2025 Earnings?

Vera Therapeutics, Inc. (NASDAQ:VERA) – Investment analysts at HC Wainwright issued their FY2025 earnings estimates for Vera Therapeutics in a research note issued on Wednesday, March 5th. HC Wainwright analyst E. Arce anticipates that the company will post earnings of ($2.40) per share for the year. The consensus estimate for Vera Therapeutics’ current full-year earnings is ($2.89) per share. HC Wainwright also issued estimates for Vera Therapeutics’ FY2026 earnings at ($1.79) EPS.

A number of other equities analysts have also recently commented on VERA. JPMorgan Chase & Co. decreased their price target on shares of Vera Therapeutics from $77.00 to $71.00 and set an “overweight” rating on the stock in a report on Tuesday. Wolfe Research assumed coverage on Vera Therapeutics in a research note on Tuesday, February 4th. They issued an “outperform” rating and a $49.00 target price on the stock. The Goldman Sachs Group assumed coverage on Vera Therapeutics in a report on Tuesday, January 28th. They issued a “buy” rating and a $58.00 price objective for the company. Wells Fargo & Company assumed coverage on Vera Therapeutics in a report on Thursday, November 21st. They set an “overweight” rating and a $70.00 price objective on the stock. Finally, Guggenheim upped their target price on Vera Therapeutics from $59.00 to $61.00 and gave the stock a “buy” rating in a research note on Thursday, February 27th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, Vera Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $64.67.

Vera Therapeutics Stock Performance

Shares of VERA opened at $28.82 on Friday. Vera Therapeutics has a 12-month low of $25.99 and a 12-month high of $51.61. The company has a current ratio of 13.76, a quick ratio of 13.76 and a debt-to-equity ratio of 0.17. The company has a market cap of $1.82 billion, a PE ratio of -11.04 and a beta of 1.17. The stock has a 50-day moving average price of $34.70 and a 200-day moving average price of $40.07.

Vera Therapeutics (NASDAQ:VERA) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.11.

Insiders Place Their Bets

In other news, CEO Marshall Fordyce sold 17,500 shares of the firm’s stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $46.94, for a total value of $821,450.00. Following the transaction, the chief executive officer now owns 85,942 shares in the company, valued at approximately $4,034,117.48. This trade represents a 16.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 52,500 shares of company stock valued at $2,305,625 in the last ninety days. Company insiders own 21.70% of the company’s stock.

Institutional Investors Weigh In On Vera Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Avoro Capital Advisors LLC grew its holdings in Vera Therapeutics by 30.2% in the 4th quarter. Avoro Capital Advisors LLC now owns 5,610,000 shares of the company’s stock worth $237,247,000 after acquiring an additional 1,300,410 shares during the last quarter. Vestal Point Capital LP bought a new stake in shares of Vera Therapeutics in the fourth quarter worth about $45,462,000. Lord Abbett & CO. LLC increased its holdings in Vera Therapeutics by 170.8% during the 4th quarter. Lord Abbett & CO. LLC now owns 1,153,670 shares of the company’s stock valued at $48,788,000 after purchasing an additional 727,656 shares during the period. Federated Hermes Inc. raised its position in Vera Therapeutics by 162.2% during the 4th quarter. Federated Hermes Inc. now owns 1,085,986 shares of the company’s stock valued at $45,926,000 after purchasing an additional 671,881 shares during the last quarter. Finally, Integral Health Asset Management LLC lifted its holdings in Vera Therapeutics by 130.0% in the 4th quarter. Integral Health Asset Management LLC now owns 1,150,000 shares of the company’s stock worth $48,634,000 after buying an additional 650,000 shares during the period. 99.21% of the stock is currently owned by institutional investors.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.